April 28, 2017
ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.
April 20, 2017
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
February 21, 2017
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
September 29, 2016
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."
July 30, 2015
Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.
January 28, 2015
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.
June 26, 2014
A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.
June 5, 2014
A recent New York Times Op-Ed highlights that, while it's possible to "repurpose" available drugs to treat patients, we don't test them because "no one stands to make money."
May 23, 2014
Dr. Jeffrey Cummings talks about the promise repurposed drugs offer to people with Alzheimer's and other dementias.
May 2, 2014
The ADDF raised more than $1.1 million at its Eighth Annual Connoisseur's Dinner to go to Jeffrey Cummings, MD in support of a clinical trial for a repurposed drug for treating Alzheimer's disease.